nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

18.04.2020 | Original Article – Clinical Oncology

Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach

verfasst von: Fuhai Ma, Bingzhi Wang, Liyan Xue, Wenzhe Kang, Yang Li, Weikun Li, Hao Liu, Shuai Ma, Yantao Tian

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The impact of neoadjuvant chemotherapy (NAC) on patients with neuroendocrine carcinoma (NEC) and mixed adenoneuroendocrine carcinoma (MANEC) of the stomach is unclear. The aim of this retrospective study was to evaluate the effects of NAC on patients with these conditions.

Methods

This study included patients with locally advanced NEC or MANEC of the stomach who underwent gastrectomy. Histologic and prognostic effects of NAC were assessed. The overall survival (OS) rate was used to compare treatment efficacies between NAC patients and surgery-first patients.

Results

Of the 69 patients included in this study, 20 received NAC and 49 underwent surgery first after diagnosis. A total of 13 patients responded to NAC (including 3 with complete remission and 10 with partial remission) and 7 patients acquired stable disease status according to the Response Evaluation Criteria in Solid Tumors version 1.1. One patient (5%) achieved a pathological complete response after NAC. Pathological tumor regression grades 1, 2, 3, 4, and 5 were observed in 1 (5%), 5 (25%), 3 (15%), 10 (50%), and 1 (5%) patient(s) with NAC, respectively. The incidence of postoperative complications was similar in the two groups. Patients in the NAC group demonstrated better OS than did patients in the surgery-first group (P = 0.032). Multivariate analyses showed that NAC, adjuvant chemotherapy, and the clinical N stage were independent factors affecting OS.

Conclusion

In patients with locally advanced NEC and MANEC of the stomach, NAC significantly improved OS.

Coccolini F, Nardi M, Montori G, Ceresoli M, Celotti A, Cascinu S, Fugazzola P, Tomasoni M, Glehen O, Catena F, Yonemura Y, Ansaloni L (2018) Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. [Journal Article; Meta-Analysis; Review; Systematic Review]. Int J Surg 51:120–127. https://doi.org/10.1016/j.ijsu.2018.01.008 CrossRefPubMed

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Magic TP (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. [Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. N Engl J Med 355(1):11–20. https://doi.org/10.1056/NEJMoa055531 CrossRefPubMed

Das M (2017) Neoadjuvant chemotherapy: survival benefit in gastric cancer. [News]. Lancet Oncol 18(6):e307. https://doi.org/10.1016/S1470-2045(17)30321-2 CrossRefPubMed

Fukuba N, Yuki T, Ishihara S, Sonoyama H, Tada Y, Kusunoki R, Oka A, Oshima N, Moriyama I, Kawashima K, Kinoshita Y (2014) Gastric mixed adenoneuroendocrine carcinoma with a good prognosis. [Case Reports; Journal Article]. Intern Med 53(22):2585–2588. https://doi.org/10.2169/internalmedicine.53.3328 CrossRefPubMed

Hashemzadeh S, Pourzand A, Somi MH, Zarrintan S, Javad-Rashid R, Esfahani A (2014) The effects of neoadjuvant chemotherapy on resectability of locally-advanced gastric adenocarcinoma: a clinical trial. [Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. Int J Surg 12(10):1061–1069. https://doi.org/10.1016/j.ijsu.2014.08.349 CrossRefPubMed

Hokonohara K, Takata A, Noda T, Imamura H, Hirota M, Oshima K, Tanida T, Hatano H, Komori T, Morita S, Iwazawa T, Akagi K, Adachi S, Dono K (2014) A case report of neuroendocrine carcinoma of the stomach with liver metastases curatively resected after neoadjuvant chemotherapy. [Case Reports; English Abstract; Journal Article]. Gan To Kagaku Ryoho 41(12):2287–2289PubMed

Ishida M, Sekine S, Fukagawa T, Ohashi M, Morita S, Taniguchi H, Katai H, Tsuda H, Kushima R (2013) Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis. [Journal Article; Research Support, Non-U.S. Gov't]. Am J Surg Pathol 37(7):949–959. https://doi.org/10.1097/PAS.0b013e31828ff59d CrossRefPubMed

Laughlin B, Scott A, Goyal U (2019) Pathologic complete response after neoadjuvant chemoradiation in a patient with gastric neuroendocrine cancer. [Case Reports]. Cureus 11(7):e5214. https://doi.org/10.7759/cureus.5214 CrossRefPubMedPubMedCentral

Lee JH, Kim HW, Kang DH, Choi CW, Park SB, Kim SH (2013) A gastric composite tumor with an adenocarcinoma and a neuroendocrine carcinoma: a case report. [Journal Article]. Clin Endosc 46(3):280–283. https://doi.org/10.5946/ce.2013.46.3.280 CrossRefPubMedPubMedCentral

Li W, Qin J, Sun YH, Liu TS (2010) Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. [Journal Article; Meta-Analysis]. World J Gastroenterol 16(44):5621–5628. https://doi.org/10.3748/wjg.v16.i44.5621 CrossRefPubMedPubMedCentral

Liao Y, Yang ZL, Peng JS, Xiang J, Wang JP (2013) Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials. [Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't]. J Gastroenterol Hepatol 28(5):777–782. https://doi.org/10.1111/jgh.12152 CrossRefPubMed

Liu DJ, Fu XL, Liu W, Zheng LY, Zhang JF, Huo YM, Li J, Hua R, Liu Q, Sun YW (2017) Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas. [Journal Article]. World J Gastroenterol 23(3):516–524. https://doi.org/10.3748/wjg.v23.i3.516 CrossRefPubMedPubMedCentral

Makuuchi R, Terashima M, Kusuhara M, Nakajima T, Serizawa M, Hatakeyama K, Ohshima K, Urakami K, Yamaguchi K (2017) Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinomas of the stomach. [Journal Article]. Biomed Res 38(1):19–27. https://doi.org/10.2220/biomedres.38.19 CrossRefPubMed

Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, Et A (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. [Journal Article; Research Support, Non-U.S. Gov't]. Cancer 73(11):2680–2686. https://doi.org/10.1002/1097-0142(19940601)73:11%3c2680:aid-cncr2820731105%3e3.0.co;2-c CrossRefPubMed

de Mestier L, Cros J (2019) Digestive system mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN). [Journal Article]. Ann Endocrinol (Paris) 80(3):172–173. https://doi.org/10.1016/j.ando.2019.04.006 CrossRef

Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA (2020) The 2019 WHO classification of tumours of the digestive system. [Journal Article]. Histopathology 76(2):182–188. https://doi.org/10.1111/his.13975 CrossRefPubMed

Nakai M, Kawasaki H, Wajima N, Kimura A, Nakayama Y, Muroya T, Yonaiyama S, Okano K, Nagase H, Hakamada K (2013) A case of mixed adenoneuroendocrine carcinoma of the esophagogastric junction treated with neoadjuvant chemotherapy. [Case Reports; Journal Article]. Gan To Kagaku Ryoho 40(12):2301–2303PubMed

Okita NT, Kato K, Takahari D, Hirashima Y, Nakajima TE, Matsubara J, Hamaguchi T, Yamada Y, Shimada Y, Taniguchi H, Shirao K (2011) Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. [Historical Article; Journal Article]. Gastric Cancer 14(2):161–165. https://doi.org/10.1007/s10120-011-0025-5 CrossRefPubMed

Oneda E, Liserre B, Bianchi D, Rota L, Savelli G, Zorzi F, Zaniboni A (2019) Diagnosis of mixed adenoneuroendocrine carcinoma (MANEC) after neoadjuvant chemotherapy for pancreatic and gastric adenocarcinoma: two case reports and a review of the literature. [Case Reports]. Case Rep Oncol 12(2):434–442. https://doi.org/10.1159/000501200 CrossRefPubMedPubMedCentral

Onoyama H, Iwasaki Y, Ohashi M, Iwanaga T, Ohinata R, Maeda Y, Omuro Y, Sasaki E, Shimoyama T, Tateishi Y (2011) A case of gastric neuroendocrine cell carcinoma successfully treated by neoadjuvant chemotherapy. [Case Reports; Journal Article; Review]. Gan To Kagaku Ryoho 38(12):2131–2133PubMed

Park JY, Ryu MH, Park YS, Park HJ, Ryoo BY, Kim MG, Yook JH, Kim BS, Kang YK (2014) Prognostic significance of neuroendocrine components in gastric carcinomas. [Journal Article; Research Support, Non-U.S. Gov't]. Eur J Cancer 50(16):2802–2809. https://doi.org/10.1016/j.ejca.2014.08.004 CrossRefPubMed

Paun I, Becheanu G, Costin AI, Constantin VD, Mihai GM, Radu L, Iovan L, Varcus F (2018) Aspects regarding nomenclature, classification and pathology of neuroendocrine neoplasms of the digestive system—a review. [Journal Article; Review]. Rom J Morphol Embryol 59(3):673–678PubMed

Russolillo N, Vigano' L, Razzore P, Langella S, Motta M, Bertuzzo F, Papotti M, Ferrero A (2015) Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: comparison of gastro-enteric and pancreatic locations. [Comparative Study; Journal Article]. Eur J Surg Oncol 41(6):751–757. https://doi.org/10.1016/j.ejso.2015.02.011 CrossRefPubMed

Shen C, Chen H, Chen H, Yin Y, Han L, Chen J, Tang S, Yin X, Zhou Z, Zhang B, Chen Z (2016) Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience. [Journal Article]. BMC Gastroenterol 16:111. https://doi.org/10.1186/s12876-016-0505-5 CrossRefPubMedPubMedCentral

van der Veen A, Seesing M, Wijnhoven B, de Steur WO, van Berge HM, Rosman C, van Sandick JW, Mook S, Haj MN, Ruurda JP, Brosens L, van Hillegersberg R (2018) Management of resectable esophageal and gastric (mixed adeno) neuroendocrine carcinoma: a nationwide cohort study. [Journal Article]. Eur J Surg Oncol 44(12):1955–1962. https://doi.org/10.1016/j.ejso.2018.07.058 CrossRefPubMed

Xie JW, Sun YQ, Feng CY, Zheng CH, Li P, Wang JB, Lin JX, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Yang YH, Huang CM (2016) Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. [Journal Article]. Eur J Surg Oncol 42(10):1464–1470. https://doi.org/10.1016/j.ejso.2016.08.004 CrossRefPubMed

Yamaguchi T, Machida N, Morizane C, Kasuga A, Takahashi H, Sudo K, Nishina T, Tobimatsu K, Ishido K, Furuse J, Boku N, Okusaka T (2014) Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. [Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't]. Cancer Sci 105(9):1176–1181. https://doi.org/10.1111/cas.12473 CrossRefPubMedPubMedCentral

Yang G, Li D, Zheng F, Yang L (2018) Long-term disease free survival of gastric mixed adenoneuroendocrine carcinoma treated with multimodality therapy: a case report. [Journal Article]. Mol Clin Oncol 8(5):653–656. https://doi.org/10.3892/mco.2018.1594 CrossRefPubMedPubMedCentral

Yoon SE, Kim JH, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST (2019) The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. [Journal Article]. J Cancer 10(14):3140–3144. https://doi.org/10.7150/jca.30355 CrossRefPubMedPubMedCentral

Zhou J, Shen J, Seifer BJ, Jiang S, Wang J, Xiong H, Xie L, Wang L, Sui X (2017) Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer. [Journal Article; Meta-Analysis; Review]. Oncotarget 8(18):30477–30494. https://doi.org/10.18632/oncotarget.12955 CrossRefPubMed

Titel: Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach
verfasst von: Fuhai Ma
Bingzhi Wang
Liyan Xue
Wenzhe Kang
Yang Li
Weikun Li
Hao Liu
Shuai Ma
Yantao Tian
Publikationsdatum: 18.04.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03214-w

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

IL-10 c.-592C>A (rs1800872) polymorphism is associated with cervical cancer

Melatonin: an endogenous miraculous indolamine, fights against cancer progression

Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials

SHCBP1 promotes tumor cell proliferation, migration, and invasion, and is associated with poor prostate cancer prognosis

Comprehensive analysis of the HOXA gene family identifies HOXA13 as a novel oncogenic gene in kidney renal clear cell carcinoma

Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie